GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Haemonetics Corp (NYSE:HAE) » Definitions » Total Assets
中文

Haemonetics (Haemonetics) Total Assets

: $2,200 Mil (As of Dec. 2023)
View and export this data going back to 1991. Start your Free Trial

Haemonetics's Total Assets for the quarter that ended in Dec. 2023 was $2,200 Mil.

Warning Sign:

If a company builds assets at 11.2% a year, faster than its revenue growth rate of 4.5% over the past 5 years, it means that the company may be getting less efficient.

During the past 12 months, Haemonetics's average Total Assets Growth Rate was 21.30% per year. During the past 3 years, the average Total Assets Growth Rate was 13.50% per year. During the past 5 years, the average Total Assets Growth Rate was 11.20% per year. During the past 10 years, the average Total Assets Growth Rate was 2.30% per year.

During the past 13 years, Haemonetics's highest 3-Year average Total Assets Growth Rate was 27.60%. The lowest was -7.20%. And the median was 5.90%.

Total Assets is connected with ROA %. Haemonetics's annualized ROA % for the quarter that ended in Dec. 2023 was 5.93%. Total Assets is also linked to Revenue through Asset Turnover. Haemonetics's Asset Turnover for the quarter that ended in Dec. 2023 was 0.16.


Haemonetics Total Assets Historical Data

The historical data trend for Haemonetics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haemonetics Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,274.77 1,267.11 1,819.92 1,859.73 1,934.83

Haemonetics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,878.07 1,934.83 1,962.26 2,011.28 2,200.43

Haemonetics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Haemonetics's Total Assets for the fiscal year that ended in Mar. 2023 is calculated as

Total Assets=Total Equity (A: Mar. 2023 )+Total Liabilities (A: Mar. 2023 )
=817.997+1116.828
=1,935

Haemonetics's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (Q: Dec. 2023 )+Total Liabilities (Q: Dec. 2023 )
=943.319+1257.109
=2,200

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Haemonetics  (NYSE:HAE) Total Assets Explanation

Total Assets is connected with ROA %.

Haemonetics's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=124.964/( (2011.275+2200.428)/ 2 )
=124.964/2105.8515
=5.93 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Haemonetics's Asset Turnover for the quarter that ended in Dec. 2023 is

Asset Turnover
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=336.25/( (2011.275+2200.428)/ 2 )
=336.25/2105.8515
=0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Haemonetics Total Assets Related Terms

Thank you for viewing the detailed overview of Haemonetics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Haemonetics (Haemonetics) Business Description

Traded in Other Exchanges
Address
125 Summer Street, Boston, MA, USA, 02110
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
Executives
Stewart W Strong officer: President, Global Hospital C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Anila Lingamneni officer: EVP, Chief Technology Officer HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Charles J Dockendorff director COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Diane M Bryant director 2200 MISSION COLLEGE BLVD, SANTA CLARA CA 95054
Josep Llorens officer: EVP, Global Manufacturing HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Michelle L Basil officer: EVP and General Counsel HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Farris Maryanne Maunsell officer: VP, Chief Accounting Officer C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Roy Galvin officer: President, Global Plasma & BC C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Laurie A. Miller officer: SVP, Human Resources C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Mark W Kroll director PO BOX 23, CRYSTAL BAY MN 55323
Dan Goldstein officer: VP, Corporate Controller HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Christopher Simon, director, officer: President & CEO HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
James Darecca officer: EVP, Chief Financial Officer C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Burke William P. Mr. officer: EVP, Chief Financial Officer HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Lloyd Emerson Johnson director 16737 NEW PROVIDENCE LANE, CHARLOTTE NC 28277